Compounded Obesity Drugs
2 articles on Compounded Obesity Drugs, written by Shotlee and medically reviewed for clinical accuracy.
Knockoff GLP-1 Market Still the Wild West: Hims Fallout
Telehealth firm Hims & Hers sparked chaos by launching a cheap compounded Wegovy pill, only to yank it days later amid FDA crackdowns and a Novo Nordisk lawsuit. This incident highlights the ongoing Wild West in the knockoff GLP-1 market. Despite resolved shortages for Wegovy and Zepbound, unregulated compounded drugs remain widely available.
5 min read
Novo Nordisk Sues Hims & Hers Over Semaglutide Patent
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
5 min read